Cancer Institute– A national cancer institute
designated cancer center

Esther M. John

Back to Profile

Publication Details

  • BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.

    Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC, Whittemore AS. Cancer Epidemiol Biomarkers Prev. 2006; 15 (10): 1863-70

    Understanding the effect of oral contraceptives on risk of breast cancer in BRCA1 or BRCA2 mutation carriers is important because oral contraceptive use is a common, modifiable practice.

    PubMedID: 17021353

Stanford Medicine Resources:

Footer Links: